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Abstract Kinase suppressor of Ras 1 (KSR1) has been
implicated in tumorigenesis in multiple cancers, including
skin, pancreatic and lung carcinomas. However, our recent
study revealed a role of KSR1 as a tumour suppressor in
breast cancer, the expression of which is potentially cor-
related with chemotherapy response. Here, we aimed to
further elucidate the KSR1-regulated signalling in response
to genotoxic agents in breast cancer. Stable isotope la-
belling by amino acids in cell culture (SILAC) coupled to
high-resolution mass spectrometry (MS) was implemented
to globally characterise cellular protein levels induced by
KSR1 in the presence of doxorubicin or etoposide. The
acquired proteomic signature was compared and GO-
STRING analysis was subsequently performed to illustrate
the activated functional signalling networks. Furthermore,
the clinical associations of KSR1 with identified targets
and their relevance in chemotherapy response were ex-
amined in breast cancer patients. We reveal a compre-
hensive repertoire of thousands of proteins identified in
each dataset and compare the unique proteomic profiles as
well as functional connections modulated by KSR1 after
doxorubicin (Doxo-KSR1) or etoposide (Etop-KSR1) sti-
mulus. From the up-regulated top hits, several proteins,
including STAT1, ISG15 and TAP1 are also found to be
positively associated with KSR1 expression in patient
samples. Moreover, high KSR1 expression, as well as high
abundance of these proteins, is correlated with better sur-
vival in breast cancer patients who underwent chemother-
apy. In aggregate, our data exemplify a broad functional
network conferred by KSR1 with genotoxic agents and
highlight its implication in predicting chemotherapy re-
sponse in breast cancer.
Keywords Breast cancer  Genotoxicity  KSR1 
Proteomics  SILAC
Introduction
KSR1 was originally identified in D. melanogaster and C.
elegans as a novel protein kinase, operating between Ras
and Raf in the Ras signalling pathway [1–3]. Intriguingly,
in the murine and human KSR1, instead of a lysine re-
quired for its kinase activity at subdomain II, an arginine
residue is invariantly present. Therefore, mammalian
KSR1 is extensively referred to as a pseudokinase [4, 5].
The role of KSR1 as a scaffolding protein was initially
demonstrated by the finding that murine KSR1 (mKSR1)
can cooperate with activated Ras to enhance MEK and
MAPK activation [6]. Moreover, KSR1 is able to translo-
cate from the cytoplasm to the plasma membrane where it
forms a complex with Raf-1, MEK1 and 14-3-3 in the
presence of activated Ras, supporting its scaffolding
function in the MAPKs pathway [7, 8]. At the same time,
the catalytic activity of KSR1 was confirmed by the fact
that tumour necrosis factor alpha (TNFa) and ceramide can
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induce KSR1 autophosphorylation and increase its capacity
to phosphorylate and activate Raf-1 [9]. A body of evi-
dence hence supports a dual function for KSR1 as an active
kinase and a scaffold protein [4].
Given its essential role in the Ras-Raf-MAPKs sig-
nalling pathway, most work has focused on studying the
function of KSR1 in Ras-dependent tumours. Indeed,
KSR1 has been shown to contribute to oncogenesis in
various forms of Ras-activated cancer, such as skin [10],
pancreatic [11] and lung carcinomas [12]. However, Ras
mutations are rare in breast cancer [13] and KSR10s
biologic functions have not been comprehensively studied
in this context. Recently, our group assessed the clinical
significance of KSR1 in breast cancer patients and revealed
a positive association of KSR1 with overall and disease-
free survival [14]. Of note, KSR1 overexpression inhibits
tumour growth both in vitro and in vivo. Moreover, KSR1
enhances BRCA1 stabilisation and diminishes its ubiqui-
tination by increasing both BARD1 abundance and
BARD1-BRCA1 interaction. Additionally, a SILAC-based
phosphoproteomics was employed to study KSR1-
modulated phospho-proteins and revealed an inhibitory
role of KSR1 in regulating p53 transcriptional activity via
DBC1 phosphorylation [15]. Interestingly, previous studies
indicated a trend in association of KSR1 expression with
response to chemotherapy and that KSR1 overexpression in
MCF7 cells increased cisplatin sensitivity and apoptosis
[14, 16]. Therefore, a profile of global protein expression
changes and KSR1-regulated signalling in response to
genotoxic agents (doxorubicin and etoposide) is needed to
further elucidate the biological functions of KSR1 in breast
cancer.
In the present study, we performed SILAC-coupled
mass spectrometry (MS) quantitative proteomics to iden-
tify and quantify the protein alterations upon KSR1 over-
expression in the presence of doxorubicin or etoposide in
MCF7 cells. We present a detailed repertoire of thousands
of proteins identified in each dataset and compare the
distinctive proteomic signature as well as functional net-
works regulated by KSR1 in response to doxorubicin
(Doxo-KSR1) or etoposide (Etop-KSR1). From the most
significantly differentiated proteins, we identify numerous
molecules, including STAT1, ISG15 and TAP1 that are
positively associated with KSR1 expression in patient
samples. Furthermore, high KSR1 expression, as well as a
high level of the characterised proteins, is correlated with
better clinical outcome in breast cancer patients who re-
ceived chemotherapy. Our data illustrate a comprehensive
functional network that KSR1 is involved in and highlight
its significance in predicting chemotherapy response in
patients.
Experimental procedures
Cell lines, reagents and plasmids
MCF7 cells were obtained from ATCC. The cells were
authenticated (STR profiling) and tested for mycoplasma
contamination every four weeks. MCF7 cells were main-
tained in SILAC medium as described below for at least
seven passages and then seeded into 100 mm dishes. All
cells were incubated at 37 C in humidified 5 % CO2.
FuGENE HD transfection reagent was obtained from
Promega. Doxorubicin and etoposide were purchased from
Sigma Aldrich. Plasmids containing human wild type
KSR1 (pCMV6-KSR1) and empty vector (pCMV6-vector)
were obtained from OriGene.
SILAC cell culture
To generate SILAC conditions, normal DMEM medium
deficient in arginine (R) and lysine (K) was complemented
with stable isotope-encoded arginine and lysine as de-
scribed previously [15]. Briefly, for ‘‘medium’’ labelling
we used L-[13C6] arginine (R6) and L-[
2H4] lysine (K4),
and for ‘‘heavy’’ labelling we used L-[13C6,
15N4] arginine
(R10) and L-[13C6,
15N2] lysine (K8). For the ‘‘light’’
condition, or unlabelled, L-[12C6,
14N4] arginine (R0) and
L-[12C6,
14N2] lysine (K0) were used. The tissue culture
media were supplemented with 10 % dialyzed fetal bovine
serum with 10 kDa MWCO, 1 % (10 mg/ml) strepto-
mycin/(10,000 units/ml) penicillin, 2 mM glutamine and
1 mM sodium pyruvate. The SILAC media were obtained
from Dundee Cell Products Ltd (Dundee, UK). MCF7 cells
were grown in these custom DMEM mediums along with
10 % dialysed FCS.
Protein digestion and peptide fractionation
Prior to protein digestion, equal amounts of protein (80 lg)
from unlabelled and labelled samples were combined.
Samples were reduced in 10 mM DTT and alkylated in
50 mM Iodoacetamide prior to boiling in loading buffer,
and then separated by one-dimensional SDS-PAGE
(4–12 % Bis–Tris Novex mini-gel, Invitrogen) and visu-
alised by colloidal Coomassie staining (Novex, Invitrogen).
The entire protein gel lanes were excised and cut into 10
slices each. Every gel slice was subjected to in-gel diges-
tion with trypsin overnight at 37 C. The resulting tryptic
peptides were extracted by formic acid (1 %) and ace-
tonitrile (CH3CN), lyophilized in a speedvac and resus-
pended in 1 % formic acid.
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Mass Spectrometry methods
Trypsin-digested peptides were separated using an Ulti-
mate 3000 RSLC (Thermo Scientific) nanoflow LC system.
On average 0.5 lg was loaded with a constant flow of 5 ll/
min onto an Acclaim PepMap100 nanoViper C18 trap
column (100 lm inner-diameter, 2 cm; Thermo Scientific).
After trap enrichment, peptides were eluted onto an Ac-
claim PepMap RSLC nanoViper, C18 column (75 lm,
15 cm; Thermo Scientific) with a linear gradient of 2–40 %
solvent B (80 % acetonitrile with 0.08 % formic acid) over
65 min with a constant flow of 300 nl/min. The HPLC
system was coupled to a linear ion trap Orbitrap hybrid
mass spectrometer (LTQ-Orbitrap Velos, Thermo Scien-
tific) via a nano electrospray ion source (Thermo Scien-
tific). The spray voltage was set to 1.2 kV, and the
temperature of the heated capillary was set to 250 C. Full-
scan MS survey spectra (m/z 335–1800) in profile mode
were acquired in the Orbitrap with a resolution of 60,000
after accumulation of 1000,000 ions. The fifteen most in-
tense peptide ions from the preview scan in the Orbitrap
were fragmented by collision-induced dissociation (nor-
malised collision energy, 35 %; activation Q, 0.250; and
activation time, 10 ms) in the LTQ Orbitrap after the ac-
cumulation of 10,000 ions. Maximal filling times were
1000 ms for the full scans and 150 ms for the MS/MS
scans. Precursor ion charge state screening was enabled,
and all unassigned charge states as well as singly charged
species were rejected. The dynamic exclusion list was re-
stricted to a maximum of 500 entries with a maximum
retention period of 180 s and a relative mass window of
15 ppm. The lock mass option was enabled for survey
scans to improve mass accuracy [17]. Data were acquired
using the Xcalibur software.
Proteome quantification
The raw mass spectrometric data files obtained for each ex-
periment were collated into a single quantitated dataset using
MaxQuant (1.3.0.5) [18] and the Andromeda search engine
software (1.3.0.5) [19]. The sequence database usedwas from
ipi.HUMAN v.3.68. Enzyme specificity was set to that of
trypsin, allowing for cleavage N-terminal to proline residues
and between aspartic acid and proline residues. Other pa-
rameters used were: (i) variable modifications, methionine
oxidation, protein N-acetylation, gln ? pyro-glu; (ii) fixed
modifications, cysteine carbamidomethylation; (iii) database:
target-decoy human MaxQuant; (iv) heavy labels: R6K4 and
R10K8; (v) MS/MS tolerance: FTMS- 10 ppm, ITMS-
0.6 Da; (vi) minimum peptide length, 6; (vii) maximum
missed cleavages, 2; (viii) maximum of labelled amino acids,
3; and (ix) false discovery rate, 1 %. Peptide ratios were cal-
culated for each arginine- and/or lysine-containing peptide as
the peak area of labelled arginine/lysine divided by the peak
area of non-labelled arginine/lysine for each single-scan mass
spectrum. Peptide ratios for all arginine- and lysine-contain-
ing peptides sequenced for each protein were averaged. Data
are normalised using 1/median ratio value for each identified
protein group per labelled sample.
KM Plotter analysis
KM Plotter online survival analysis, which collates a mas-
sive dataset of gene expression data and survival informa-
tion of more than 3000 patients, was used [20]. The
expression levels of KSR1, ISG15, STAT1, TAP1, MX1 and
HLA-C were selected. The relevance on relapse free sur-
vival (RFS) in breast cancer patients who received system-
atic chemotherapy was assessed. A survival curve with the
hazard ratio (HR) with 95 % confidence intervals and lo-
grank P value was displayed. The generated P value does
not include correction for multiple hypothesis testing.
Bioinformatics and statistical analyses
All the bioinformatic analysis was performed in R [21] and
SWI-Prolog [22], using Real [23] for connecting the two
systems. To characterise the top hits in different datasets,
SignificantB testwasperformedandP\ 0.05was considered
significant [18]. To visualise the modulated proteomics, the
heatmap of quantified values showing the overall pattern of
regulation was displayed. GO analysis was performed at the
level 2 of the three GO domains: biologic process (BP), cel-
lular component (CC) and molecular function (MF) [24].
Furthermore, the hyper-geometric test from GOstats package
was used to identify GO terms that are enriched in the de-
regulated genes in each condition [25]. For every overrepre-
sented GO term, a network connecting de-regulated genes in
this GO termwas drawn showing the networks amongst these
genes in the STRING protein–protein interactions database
[26]. Only edges with a confidence value greater than 500
were included (range: 0–999). Prolog was used for the overall
control of our pipeline and the graph operations on the
STRING database. The correlation analysis of gene expres-
sions from TCGA dataset was performed using GraphPad
Prism V5.0 (GraphPad Software, San Diego, CA).
Results
Establishing a quantitative proteomics approach
to identify global protein changes induced by KSR1
in response to doxorubicin or etoposide
To characterise and compare the global proteomic alter-
ations prompted by KSR1 in the presence of doxorubicin or
Breast Cancer Res Treat (2015) 151:555–568 557
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etoposide, we conducted a triple-labelling SILAC strategy
coupled to high-resolution quantitative MS as readily
validated in our two recent studies [15, 27]. Following cell
labelling, in the doxorubicin-KSR1 (Doxo-KSR1) set,
R0K0 (Light (L)), R6K4 (Medium (M)) and R10K8
(Heavy (H)) labelled cells were treated with control
(DMSO), overexpression of KSR1 (24 h) in the presence of
doxorubicin (1 lm, 2 h) or doxorubicin only, respectively
(Fig. 1a). In the etoposide-KSR1 (Etop-KSR1) set, R0K0,
R6K4 and R10K8 labelled cells were treated with control
(DMSO), overexpression of KSR1 (24 h) in the presence of
etoposide (40 lm, 3 h) or etoposide alone, respectively
(Fig. 1b).
For each analysis, from more than 20,000 non-redundant
peptide sequences, a proteome comprising more than 2000
distinguishable and unambiguously identified proteins was
assembled with a minimum of two peptides with a false
discovery rate (FDR) of 1 % (minimal peptide length 7 aa).
Detailed information for each identified protein, including
protein IDs, number of peptides used for identification and
their sequence and % coverage, normalised fold changes
and log2 ratios are shown in Supplementary Table S1. The
log2 ratios’ distribution shows the excellent quantitative
precision of the experiment (Supplementary Fig. 1). In
total, approximately 2000 proteins were identified in Doxo-
KSR1 and Etop-KSR1 sets and their distribution according
to fold changes was determined. Around 85 % of the
proteome identified in Doxo-KSR1 and Etop-KSR1 was
identical, highlighting a very high degree of overlap and
consistency (Fig. 2a). We then used Significant B test to
distinguish the most differentiated proteins in each dataset
(P\ 0.05 according to Significance B test) [18].
Global proteomic alterations induced
by doxorubicin or etoposide in MCF7
Firstly, we sought to assess the global proteomic changes
induced by doxorubicin or etoposide alone, two major
genotoxic agents in cancer treatment. The H/L ratios rep-
resenting Doxo/Control or Etop/Control from two acquired
datasets were analysed and compared to delineate a com-
prehensive proteomic profile contributed by different
genotoxic drugs. A total of 164 proteins were significantly
modulated upon doxorubicin stimulus, whereas 162 mole-
cules were markedly differentiated in response to etoposide
(Fig. 2b). Specifically, 93 proteins showed significant up-
regulation and 71 were down-regulated upon doxorubicin
treatment. There was a pronounced increase in expression
of 96 molecules in the presence of etoposide, while a de-
crease was evident in the levels of 66 proteins (Fig. 2c).
Interestingly, there were 70 mutual proteins greatly af-
fected by doxorubicin and etoposide, among which 45 were
up-regulated and 25 were down-regulated (Fig. 2b, c).
Heatmaps showing the commonly regulated proteins
upon doxorubicin and etoposide stimulus were generated to
highlight the similarity in their proteomic changes, whereas
the ones belonging specifically to either doxorubicin or
etoposide response were compared and presented (Fig. 2d).
Furthermore, to distinguish the top hits upon doxorubicin
or etoposide stimulus, the Log2 ‘normalized ratios’ (H/L)
were plotted against Log10 ‘intensity’ (H/L) to demon-
strate the significantly differentiated proteins, which were
catalogued according to P values from Significant B test
(Fig. 3a). A list of top 30 proteins that are significantly
regulated in response to either doxorubicin or etoposide is
presented in Supplementary Table S2.
In the characterised proteome, a profile of differentially
modulatedproteins and associatedpathways induced byeither
doxorubicin or etoposide alone was revealed. To gain insights
into the distinctively affected cellular activities, the top GO
categories to which the differential proteins belong were un-
covered.GOanalysis on cellular components (CC), biological
processes (BP) and molecular function (MF) was subse-
quently performed. In terms of the localisation of the identi-
fied proteins, upon doxorubicin or etoposide stimulus, a
similar distribution between membrane/cytoplasmic and nu-
clear cell components was observed (Supplementary Fig. 2).
Molecular functions, such as transporter activity, structural
molecule activity, enzyme regulator activity and binding ac-
tivity, were amongst the most affected ones in response to
doxorubicin or etoposide (Supplementary Fig. 2). Moreover,
a number of associated biological processes were unveiled,
including cell cycle, growth, apoptosis, transport, immune
system and cell adhesion, highlighting a broad effect of both
doxorubicin and etoposide on cell fate (Fig. 4a).
We then incorporated the STRING database with the GO
analyses to define the functional protein–protein interaction
networks induced by doxorubicin or etoposide [26]. Not sur-
prisingly, a large number of functional connections were af-
fected, such as mRNA splicing, cell killing and immune
system process. A comparison of the signalling networks af-
fected by either doxorubicin or etoposide showed a good
overlap, supporting a similar mechanism of their genotoxic
action. Conversely, differences were also observed. Doxoru-
bicin showed a greater effect on metabolic process, whereas
etoposide had a more pronounced impact on translational
initiation, elongation, termination and cell surface receptor
signalling. Representatives of the most enriched functional
networks are displayed (Supplementary Fig. 3).
Global proteomic alterations induced by KSR1
overexpression in response to doxorubicin
or etoposide
Although KSR1 has been indicated to play a potential role
in chemotherapy response in breast cancer, a detailed
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proteomic picture and related signalling networks induced
by genotoxic agents, which would further improve our
understanding of its function, are still lacking [14, 16].
Therefore, we next determined the global proteome alter-
ations upon KSR1 overexpression in the presence of dox-
orubicin or etoposide.
The quantifications of corresponding M/L ratios show-
ing (Doxo?KSR1)/Control or (Etop?KSR1)/Control from
two datasets were evaluated and then compared to provide
a complete proteomic repertoire. In summary, upon KSR1
overexpression, there were 157 and 171 proteins greatly
modulated in the presence of doxorubicin or etoposide,
Fig. 1 Strategy to identify global protein changes induced by KSR1
in response to doxorubicin or etoposide. a Three SILAC labeled cell
populations were subjected to DMSO (Control), treatment with KSR1
overexpression in the presence of doxorubicin, and treatment with
doxorubicin alone. Subsequently, total protein lysates were prepared,
and light, medium, and heavy cell populations were mixed 1:1:1,
digested and fractionated to peptides. SILAC labelled peptides were
then processed through LC–MS/MS. The peptides were then identi-
fied and quantified using quantitation software MaxQuant. b Similarly,
cells were treated with DMSO (Control), treatment with KSR1
overexpression in the presence of etoposide, and treatment with
etoposide alone. The acquired lysates were subject to same protocol
as described above
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respectively (Fig. 2b). Moreover, 88 proteins showed
substantial up-regulation and 69 were down-regulated in
the Doxo?KSR1 dataset, whereas 98 and 73 were sig-
nificantly up or down modulated in the Etop?KSR1
dataset (Fig. 2c). Among these, 92 were commonly af-
fected with 57 showing an increase and 35 a decrease in
their protein levels (Fig. 2b, c).
Similarly, to visualise the proteomic changes, we created
heatmaps highlighting the mutual targets induced by KSR1
in response to doxorubicin or etoposide, as well as the ones
bFig. 2 Global proteomic alterations affected by KSR1 in the
presence of doxorubicin or etoposide. a Venn diagram showing a
very high degree of overlap and consistency of the proteome
identified in Doxo-KSR1 and Etop-KSR1 datasets. b Venn diagram
showing the counts of proteins significantly modulated upon doxoru-
bicin or etoposide stimulus (H/L), and proteins markedly differenti-
ated by KSR1 in the presence of doxorubicin or etoposide (M/L),
according to Significant B test (P\ 0.05). c Venn diagram showing
the numbers of proteins significantly up- or down-regulated in each
dataset. d Heatmaps showing the commonly and exclusively regulat-
ed proteins upon doxorubicin or etoposide stimulus (upper panel),
and proteins significantly affected by KSR1 in the presence of
doxorubicin or etoposide (lower panel)
Fig. 3 Distribution of protein ratios from identified proteome in two
datasets. Volcano plots showing the Log2 ‘normalized ratios’ (M/L)
against Log10 ‘intensity’ (M/L) for each characterised protein in
response to doxorubicin or etoposide stimulus (a), and affected by
KSR1 in the presence of doxorubicin or etoposide (b). Proteins are
displayed based on P values from Significant B test. Blue circles are
proteins with a P value of\0.001; yellow are proteins with a P value
between 0.001 and 0.01; red represent P values between 0.01 and
0.05; grey are proteins whose fold change is not significant
(P[ 0.05). KSR1 is highlighted showing a pronounced increase in
its protein abundance, supporting a good reproducibility and accuracy
of the technique (b)
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exclusively belonging to either Doxo-KSR1 or Etop-KSR1
(Fig. 2d). In addition, to characterise the evident hits upon
KSR1 overexpression in the presence of doxorubicin or
etoposide, the Log2 ‘normalized ratios’ (M/L) were plotted
against Log10 ‘intensity’ (M/L) to exhibit the significantly
differentiated proteins based on P values from Significant
Fig. 4 Characterization of the
functional portrait conferred by
KSR1 in the presence of
doxorubicin or etoposide.
a Functional profiles of top GO
biologic processes affected by
doxorubicin or etoposide
stimulus (H/L), or by KSR1 in
the presence of doxorubicin or
etoposide (M/L) are presented.
x-axis shows the percentage of
hits that belong to a GO biologic
process term. b The functional
protein–protein interaction
networks belonging exclusively
to Doxo-KSR1 or Etop-KSR1
are shown. Protein nodes with
lighter colour are up-regulated,
whereas darker colour
represents down-regulation
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B test (Fig. 3b). A marked increase in protein abundance of
KSR1 itself was also recorded, confirming a good repro-
ducibility and accuracy of SILAC-based proteomics
(Fig. 3b). Lists of the top 30 proteins that are significantly
regulated byDoxo-KSR1 (Table 1) or Etop-KSR1 (Table 2)
are presented.We then investigated the proteomic changes in
more detail to unveil the biological processes and molecular
functions conferred by KSR1 overexpression in response to
doxorubicin or etoposide. GO localisation analysis revealed
that the identified proteins from KSR1-Doxo and KSR1-E-
top datasets are disseminated in numerous cellular compo-
nents, including extracellular matrix, cell membrane,
cytoplasm, nuclei, synapse and other organelles (Supple-
mentary Fig. 2). Likewise, they are implicated in a broad
range of biological processes, including cell communication,
apoptosis, response to stimulus, growth, transport, devel-
opment and cell adhesion (Fig. 4a).
We next sought to define the exclusive as well as shared
modulated functional protein–protein interaction networks in
the two datasets to further address the action of KSR1 in
response to different genotoxic agents. From the significantly
differentiated proteins, we selected candidates according to
their appearance only in the Doxo-KSR1 (65 proteins,
Fig. 2d) or the Etop-KSR1 (79 proteins, Fig. 2d) dataset or in
both (92 proteins, Fig. 2d) for follow-up analysis. We first
determined GO terms that were enriched in these three dif-
ferent groups of proteins and then portrayed the STRING
network for each group with an overrepresented GO term. As
expected, broadly integrated functional networks were un-
covered. Of note, a unique profile of functional connections
stimulated by KSR1 with doxorubicin or etoposide was de-
lineated, highlighting the discrepancies of KSR1-regulated
signalling in different contexts. For Doxo-KSR1, the most
overrepresented exclusive functional networkswere related to
Table 1 A list of top 30
proteins that are significantly
regulated by KSR1
overexpression in the presence
of doxorubicin
Symbols GeneIDs Full descriptions P value
SYT7 9066 Synaptotagmin VII 7.16E-39
IFIT2 3433 Interferon-induced protein with tetratricopeptide repeats 2 4.63E-32
IFIT1 3434 Interferon-induced protein with tetratricopeptide repeats 1 4.20E-31
MX1 4599 MX dynamin-like GTPase 1 2.15E-30
KSR1 8844 Kinase suppressor of ras 1 2.28E-27
DDX58 23586 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 8.26E-27
SYCP1 6847 Synaptonemal complex protein 1 1.59E-25
OAS3 4940 20-50-oligoadenylate synthetase 3, 100 kDa 1.85E-21
IFIT3 3437 Interferon-induced protein with tetratricopeptide repeats 3 7.28E-21
ISG15 9636 ISG15 ubiquitin-like modifier 7.04E-19
OAS2 4939 20-50-oligoadenylate synthetase 2, 69/71 kDa 8.13E-18
IFIH1 64135 Interferon induced with helicase C domain 1 2.52E-17
TADA2B 93624 Transcriptional adaptor 2B 3.89E-17
DDX60 55601 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 1.57E-16
SAMD9 54809 Sterile alpha motif domain containing 9 8.87E-16
PARP14 54625 Poly (ADP-ribose) polymerase family, member 14 2.63E-14
PARP9 83666 Poly (ADP-ribose) polymerase family, member 9 5.30E-14
OASL 8638 20-50-oligoadenylate synthetase-like 2.53E-13
WARS 7453 Tryptophanyl-tRNA synthetase 1.93E-12
STAT1 6772 Signal transducer and activator of transcription 1, 91 kDa 2.11E-12
LGALS3BP 3959 Lectin, galactoside-binding, soluble, 3 binding protein 3.27E-12
HLA-C 3107 Major histocompatibility complex, class I, C 7.35E-12
RNF213 57674 Ring finger protein 213 5.16E-10
SAMHD1 25939 SAM domain and HD domain 1 2.44E-09
TAP1 6890 Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 2.51E-09
OAS1 4938 20-50-oligoadenylate synthetase 1, 40/46 kDa 3.38E-09
ICAM1 3383 Intercellular adhesion molecule 1 3.62E-09
PML 5371 Promyelocytic leukaemia 3.66E-09
HELZ2 85441 Helicase with zinc finger 2, transcriptional coactivator 9.35E-09
HLA-A 3105 Major histocompatibility complex, class I, A 1.65E-08
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apoptosis, rRNAmetabolic processes, ncRNAprocessing and
nucleotide biosynthesis (Fig. 4b). Conversely, for Etop-
KSR1, the most enriched functional connections were found
to be cellular secretion, response to cytokine stimulus, Notch
signalling,wound healing, transcription initiation and vesicle-
mediated transport (Fig. 4b).
Clinical significance of SILAC-based proteomics
identified targets in breast cancer
From the top hits modulated by KSR1 in the presence of
genotoxic agents, some proteins, which were up-regulated
upon KSR1 overexpression in the presence of genotoxic
agents, have been previously indicated to play a role in
doxorubicin or etoposide response, including ISG15 [28],
STAT1 [29–32], TAP1 [33], MX1 [34] and HLA-C [35]
(Tables 1, 2). Of note, recent work has shown that doxoru-
bicin increased levels of the posttranslational modifier
ISG15, which resulted in ISGylation of the p53 family
protein. As a result, ISGylation inhibited the capability of
DNp63a to stimulate anchorage-independent cell growth
and tumour formation in vivo as well to repress the activity
of proapoptotic p53 family members. These findings indi-
cate a tumour suppressive role for ISG15 and highlight a
molecular rationale for therapeutic use of doxorubicin [28].
Moreover, chemotherapeutic drugs, such as doxorubicin,
can induce the activation of STAT1 and enhance the co-
operation of p53 and STAT1 in the induction of cell death
[30]. In breast cancer, the dual EGFR/HER2 tyrosine kinase
inhibitor lapatinib and doxorubicin enhance the STAT1-
dependent antitumour immune response [36, 37]. Consis-
tently, our proteomic data also showed significant increase
levels of ISG15 and STAT1 upon chemotherapeutic drugs
and supports their role as responsive markers.
To further examine the clinical associations of KSR1
with ISG15, STAT1, TAP1, MX1 and HLA-C and their
Table 2 A list of top 30
proteins that are significantly
regulated by KSR1
overexpression in the presence
of etoposide
Symbols GeneIDs Full descriptions P value
OAS2 4939 20-50-oligoadenylate synthetase 2, 69/71 kDa 3.18E-33
MX1 4599 MX dynamin-like GTPase 1 2.97E-32
IFIT1 3434 Interferon-induced protein with tetratricopeptide repeats 1 7.00E-31
IFIT2 3433 Interferon-induced protein with tetratricopeptide repeats 2 1.24E-29
DDX58 23586 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 1.92E-24
OAS3 4940 20-50-oligoadenylate synthetase 3, 100 kDa 6.84E-21
HLA-C 3107 Major histocompatibility complex, class I, C 9.21E-21
KSR1 8844 Kinase suppressor of ras 1 1.92E-19
CFB 629 Complement factor B 5.48E-19
ISG15 9636 ISG15 ubiquitin-like modifier 1.10E-18
IFIH1 64135 Interferon induced with helicase C domain 1 4.79E-18
IFIT3 3437 Interferon-induced protein with tetratricopeptide repeats 3 4.91E-18
SPRR2C 6702 Small proline-rich protein 2C (pseudogene) 3.18E-17
DDX60 55601 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 2.97E-16
HELZ2 85441 Helicase with zinc finger 2, transcriptional coactivator 6.21E-16
MX2 4600 MX dynamin-like GTPase 2 7.51E-16
WARS 7453 Tryptophanyl-tRNA synthetase 1.21E-15
ICAM1 3383 Intercellular adhesion molecule 1 1.91E-15
PARP14 54625 Poly (ADP-ribose) polymerase family, member 14 1.33E-14
FABP5 2171 Fatty acid binding protein 5 (psoriasis-associated) 1.60E-14
SAMD9 54809 Sterile alpha motif domain containing 9 3.67E-14
OAS1 4938 20-50-oligoadenylate synthetase 1, 40/46 kDa 7.40E-14
STAT1 6772 Signal transducer and activator of transcription 1, 91 kDa 1.96E-13
LGALS3BP 3959 Lectin, galactoside-binding, soluble, 3 binding protein 1.71E-12
LGALS7 3963 Lectin, galactoside-binding, soluble, 7 5.08E-12
S100A8 6279 S100 calcium binding protein A8 1.97E-11
RSAD2 91543 Radical S-adenosyl methionine domain containing 2 8.80E-11
TRANK1 9881 Tetratricopeptide repeat and ankyrin repeat containing 1 1.47E-10
OASL 8638 20-50-oligoadenylate synthetase-like 3.64E-10
STAT2 6773 Signal transducer and activator of transcription 2, 113 kDa 7.00E-10
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relevance in chemotherapy response, we carried out a
series of analyses using extensive data from breast cancer
patients. First, we took advantage of gene expression data
from the well-established The Cancer Genome Atlas
(TCGA) dataset [38] and analysed the mRNA expression
correlation of KSR1 with ISG15, STAT1, TAP1, MX1 and
HLA-C individually in approximately 600 breast cancer
patients. A trend of potential positive correlations of KSR1
mRNA with ISG15, STAT1, TAP1, MX1 and HLA-C was
observed, supporting our proteomic data (Fig. 5a).
Next, we utilised the survival analysis tool KM Plotter,
which incorporates comprehensive gene expression data
and survival information from more than 3000 patients [20].
The relevance of the levels of KSR1, ISG15, STAT1,
TAP1, MX1 and HLA-C on relapse free survival (RFS) in
breast cancer patients who received chemotherapy was
analysed. Interestingly, high KSR1 expressions are sig-
nificantly associated with better survival in this subgroup of
patients (Fig. 5b), supporting our previous finding of KSR1
acting as a tumor suppressor [14]. Likewise, KM Plotter
analysis also demonstrated pronounced correlations be-
tween high levels of ISG15, STAT1, TAP1 and HLA-C,
which were positively regulated upon KSR1 overexpression
in the presence of genotoxic agents, with longer relapse
free survival in patients who underwent chemotherapy
(Fig. 5b).
Discussion
KSR1 was originally characterised as an evolutionary
conserved protein kinase in the Ras signalling pathway in
Drosophila and Caenorhabditis elegans [1–3], whereas
mammalian KSR1 is broadly described as a pseudokinase
due to the absence of a key lysine residue essential for its
kinase activity [4, 5]. Recently, emerging evidence
demonstrates dual function of mammalian KSR1 as an
active kinase and a scaffold protein in the Ras-Raf-MAPK
pathway [4]. Given its importance in this oncogenic sig-
nalling cascade, a number of studies attempted to address
the role of KSR1 in Ras-dependent cancers. KSR1 has been
shown to contribute to oncogenesis, while deficiency of
KSR1 prevents Ras signalling and tumour development in
various types of cancer, including skin and pancreatic [10–
12]. However, in breast cancer where Ras mutations are
rare [13], several lines of evidence suggest that KSR1 plays
a different role. Firstly, KSR1 may not act as a positive
regulator of the canonical Ras-RAF-MAPKs pathway, as
no significant changes were observed in the phosphoryla-
tion of major members of this pathway, (i.e. ERK1/2),
upon KSR1 overexpression [14]. Secondly, KSR1 up-
regulation inhibited breast cancer growth in vitro and
in vivo, whereas breast cancer patients with high KSR1 had
better disease-free and overall survival [14]. Moreover,
KSR1 overexpression in MCF7 cells enhanced cisplatin
sensitivity and apoptosis and a trend correlation of KSR1
expression with patients’ response to chemotherapy was
indicated [14, 16]. Therefore, a detailed profile of KSR1-
regulated signalling in response to genotoxic agents is
needed to improve our understanding of its role in breast
cancer.
Here, we implemented SILAC-based high-resolution
MS quantitative proteomics to identify and quantify global
protein changes upon KSR1 overexpression in the presence
of either doxorubicin or etoposide in MCF7 cells. Dox-
orubicin and etoposide are widely used anticancer agents
that target human type IIA topoisomerases (Top2) resulting
in the inhibition of DNA replication [39, 40]. Although
both drugs are Top2 poisons, not only do the kinetics of
formation of Top2 cleavage complexes (Top2 cc) differ
(slow in the case of doxorubicin to very rapid in the case of
etoposide), but also the numbers of Top2-mediated DNA
double-strand breaks (DSB) and single-strand breaks (SSB)
vary [40]. Moreover, the cellular response to Top2 in-
hibitors is complex and a broad range of DNA processes
are implicated. Thanks to the SILAC-based quantitative
proteomics, we were able to quantify and compare the
affected proteome in response to doxorubicin and etopo-
side. As expected, a large number of proteins were sig-
nificantly modulated upon doxorubicin and etoposide
stimulus, whereas approximately 70 of them were mutually
identified in both treatments. GO-STRING analysis re-
vealed multiple signalling networks activated by doxoru-
bicin and etoposide and supports the complexity of the
cellular response to Top2 poisons. Of note, a good overlap
of biological processes perturbed by either doxorubicin or
etoposide was observed, highlighting the similarity in their
mechanism of action in cytotoxicity. Consistently, dis-
crepancies also exist in downstream effects, as doxorubicin
and etoposide surely have additional targets besides Top2
[40]. For instance, metabolic processes were more enriched
upon doxorubicin stimulus, whereas translational initiation,
elongation and termination were more pronounced when
after etoposide treatment. Further elucidation of doxoru-
bicin- or etoposide- exclusive targets will shed new light on
the mechanism of action of these Top2 drugs.
Clearly, the biological function of KSR1 in breast can-
cer is different from its role in other Ras-dependent tu-
mours. Previously, we reported a tumour suppressive
action of KSR1 in breast cancer by stabilising BRCA1
through a reduction of its ubiquitination and by promoting
the BRCA1-BARD1 interaction. Moreover, a trend in
correlation of KSR1 expression with response to che-
motherapy was indicated and KSR1 abundance in MCF7
cells was positively associated with cisplatin sensitivity
and apoptosis [14, 16]. These data support KSR1 in a
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Fig. 5 Clinical significance of SILAC-based proteomics identified
targets in breast cancer. a The correlation analysis of KSR1 mRNA
with ISG15, STAT1, TAP1, MX1 and HLA-C gene expressions from
TCGA dataset. b Kaplan–Meier curves show associations of
expression levels of KSR1, STAT1, ISG15, TAP1 and HLA-C with
relapse free survival (RFS) in breast cancer patients who underwent
systematic chemotherapy
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continuum with clinical relevance and position KSR1 in
the major oncoprotein pathways in breast tumorigenesis.
Importantly, it led us to further investigate the KSR1-
regulated proteome and associated signalling in response to
genotoxic agents. To our knowledge, this is the first global
analysis comparing the proteomic profiles induced by
KSR1 in the presence of doxorubicin or etoposide. Ap-
proximately two hundred proteins were significantly af-
fected upon KSR1 overexpression after either doxorubicin
or etoposide treatment. Of note, a large number of these
identified proteins were commonly affected in both treat-
ments, indicating a high degree of similarity in KSR1-
regulated proteome induced by genotoxic agents.
In-depth GO analysis confirmed a resemblance in both
cellular component distributions and biological processes
revealed in KSR1-Doxo and KSR1-Etop datasets. More-
over, we delineated a distinctive signature of functional
signalling networks regulated by proteins in the KSR1-
Doxo or KSR1-Etop dataset, indicating a certain degree of
discrepancies in the KSR1-regulated proteome in response
to different drugs. Apoptosis, rRNA metabolic process,
ncRNA processing and nucleotide biosynthesis were
amongst the most enriched functional connections for
Doxo-KSR1, whereas cellular secretion, response to cy-
tokine stimulus, Notch signalling, wound healing, tran-
scription initiation and vesicle-mediated transport were
characterised for Etop-KSR1. In concordance with our
work, previous studies have documented an important role
of KSR1 in cytokine-induced apoptosis [41, 42], a pro-
tective factor against bacterial infection [43], as well as an
essential player in regulating glucose tolerance and insulin
sensitivity [44]. These data suggest diverse effects con-
ferred by KSR1 and add complexity to the KSR1-regulated
signalling, which requires future investigation.
Furthermore, from the modulated proteomic profile, we
identified a number of KSR1-regulated genes that are
implicated in chemotherapy response in breast cancer. The
expression levels of these proteins, including ISG15,
STAT1, TAP1, MX1 and HLA-C, were up-regulated upon
KSR1 overexpression in the presence of genotoxic agents.
Likewise, this similar trend of positive correlations of
KSR1 mRNA levels with ISG15, STAT1, TAP1, MX1 and
HLA-C was also seen in the tumour samples from the
TCGA database. Of note, high expression levels of KSR1,
as well as the identified proteins ISG15, STAT1, TAP1
and HLA-C, are correlated with better outcome in patients
who underwent chemotherapy. These findings which are
consistent with previous results support their role in dox-
orubicin or etoposide response, highlighting the tumour
suppressive action of KSR1 [14], ISG15 [28] and
STAT1 [36].
Additional work is required to examine the KSR1-
regulated proteome in detail, such as investigation of the
identified signalling pathways in MCF7 and other models.
Moreover, it would also be interesting to address the un-
derlying mechanism by which KSR1 facilitates the ex-
pression of ISG15, STAT1, TAP1, MX1 and HLA-C in the
case of genotoxic agents.
Collectively, we present a comprehensive profile of
KSR1-regulated proteome in the presence of genotoxic
agents, as well as distinct functional networks belonging
exclusively to Doxo-KSR1 and Etop-KSR1. Notably,
our results also underscore the clinical relevance of
KSR1 expression in chemotherapy response in breast
cancer patients.
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